Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved
pharmacotherapies have demonstrated limited effectiveness over the last few decades in …

The opioid overdose epidemic, which has been markedly exacerbated by fentanyl,
highlights the urgency for psychiatrists to be well versed on the proper screening and …

The potential of psychedelics to persistently treat substance use disorders is known since
the 1960s. However, the biological mechanisms responsible for their therapeutic effects …

Psilocybin is the main psychoactive compound found in hallucinogenic/magic mushrooms
and can bind to both serotonergic and tropomyosin receptor kinase b (TrkB) receptors …

Background: The classical psychedelics psilocybin, peyote, ayahuasca/N, N-
dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of …

Background Persons with schizophrenia are excluded from psychedelic-assisted therapy
due to concerns about the risk of triggering or worsening psychosis. However, there is …

This systematic review analyzes the current literature on the potential therapeutic use of
classic psychedelics (ie, psilocybin, lysergic acid diethylamide [LSD], N, N …

Introduction A new era of treatment for adults with treatment-resistant depression (TRD),
which involves psychedelic substances, is dawning. Emerging evidence indicates that …

Introduction Depression is a common disabling psychiatric disorder, which–in extreme
cases–may lead to suicide if untreated or inadequately treated. Despite the availability of …

Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide
leading to physical, mental and socio-economic consequences. While current treatments for …